Bluebird Stock Today

BLUE
 Stock
  

USD 8.49  0.88  11.56%   

Market Performance
7 of 100
Odds Of Distress
Less than 21
Bluebird Bio is trading at 8.49 as of the 4th of December 2022, a 11.56 percent increase since the beginning of the trading day. The stock's lowest day price was 7.4. Bluebird Bio has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Bluebird Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of November 2021 and ending today, the 4th of December 2022. Click here to learn more.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. The company has 82.91 M outstanding shares of which 19.27 M shares are currently shorted by private and institutional investors with about 4.58 trading days to cover. More on Bluebird Bio

Bluebird Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bluebird Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bluebird Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bluebird Bio is way too risky over 90 days horizon
Bluebird Bio appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 3.66 M. Net Loss for the year was (819.38 M) with loss before overhead, payroll, taxes, and interest of (351.14 M).
Bluebird Bio currently holds about 132.51 M in cash with (635.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Bluebird Bio has a frail financial position based on the latest SEC disclosures
Over 81.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Bluebird Bio to Receive Much-Needed Cash Infusion From Fast Pass Sale - Bloomberg
CEO and President and DirectorNick Leschly
Fama & French Classification
Average Analyst Recommendation
Analysts covering Bluebird Bio report their recommendations after researching Bluebird Bio's financial statements, talking to executives and customers, or listening in on Bluebird Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bluebird Bio. The Bluebird consensus assessment is calculated by taking the average forecast from all of the analysts covering Bluebird Bio.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Bluebird Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Bluebird Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted74.4 M68.9 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares74.4 M68.9 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(652.4 M)(635.6 M)
Fairly Down
Decreasing
Slightly volatile
Current Liabilities165.1 M153 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities202.5 M219.5 M
Significantly Down
Increasing
Slightly volatile
Gross Margin86.988.06
Fairly Down
Decreasing
Slightly volatile
Total Debt116.3 M89.6 M
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.00320.0031
Fairly Up
Increasing
Very volatile
Current Assets463.6 M336.5 M
Significantly Up
Increasing
Slightly volatile
Total Assets743.1 M593.8 M
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bluebird Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Bluebird Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bluebird Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bluebird Bio's financial leverage. It provides some insight into what part of Bluebird Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Bluebird Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Bluebird Bio deploys its capital and how much of that capital is borrowed.
Liquidity
Bluebird Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 292.97 M in liabilities with Debt to Equity (D/E) ratio of 1.63, which is about average as compared to similar companies. Bluebird Bio has a current ratio of 1.1, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist Bluebird Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Bluebird Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bluebird Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bluebird to invest in growth at high rates of return. When we think about Bluebird Bio's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(652.37 Million)
Bluebird Bio (BLUE) is traded on NASDAQ Exchange in USA and employs 518 people. Bluebird Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 630.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bluebird Bio's market, we take the total number of its shares issued and multiply it by Bluebird Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bluebird Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.91 M outstanding shares of which 19.27 M shares are currently shorted by private and institutional investors with about 4.58 trading days to cover. Bluebird Bio currently holds about 132.51 M in cash with (635.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Check Bluebird Bio Probability Of Bankruptcy
Ownership
Bluebird Bio retains a total of 82.91 Million outstanding shares. The majority of Bluebird Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bluebird Bio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bluebird Bio. Please pay attention to any change in the institutional holdings of Bluebird Bio as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Bluebird Ownership Details

Bluebird Stock Price Odds Analysis

What are Bluebird Bio's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Bluebird Bio jumping above the current price in 90 days from now is near 1%. The Bluebird Bio probability density function shows the probability of Bluebird Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.0986 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bluebird Bio will likely underperform. Additionally, the company has an alpha of 0.5618, implying that it can generate a 0.56 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 8.49HorizonTargetOdds Above 8.49
99.71%90 days
 8.49 
0.29%
Based on a normal probability distribution, the odds of Bluebird Bio to move above the current price in 90 days from now is near 1 (This Bluebird Bio probability density function shows the probability of Bluebird Stock to fall within a particular range of prices over 90 days) .

Bluebird Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Bluebird Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bluebird Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bluebird Bio's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.5 K36 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.5 K75 K
View Bluebird Bio Diagnostics

Bluebird Bio Historical Income Statement

Bluebird Bio Income Statement is one of the three primary financial statements used for reporting Bluebird's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bluebird Bio revenue and expense. Bluebird Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Bluebird Bio Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 44.69 Million. The current year Revenues is expected to grow to about 3.8 M, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to (841.6 M). View More Fundamentals

Bluebird Stock Against Markets

Picking the right benchmark for Bluebird Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bluebird Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bluebird Bio is critical whether you are bullish or bearish towards Bluebird Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bluebird Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

Bluebird Bio Corporate Directors

Bluebird Bio corporate directors refer to members of a Bluebird Bio board of directors. The board of directors generally takes responsibility for the Bluebird Bio's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bluebird Bio's board members must vote for the resolution. The Bluebird Bio board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Elizabeth Pingpank - Director CommunicationsProfile
James Mandell - DirectorProfile
John Maraganore - Independent DirectorProfile
Manisha Pai - Sr. Director, Investor RelationsProfile

Invested in Bluebird Bio?

The danger of trading Bluebird Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bluebird Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bluebird Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bluebird Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for analysis

When running Bluebird Bio price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Is Bluebird Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bluebird Bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Bluebird Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.